Janus Kinase Inhibitors - JAK's have shown to be successful in a variety of different disease indications. The science of these inhibitors is still in the early stages of understanding. They operate by inhibiting one or more of the family of enzymes, (JAK1, JAK2, JAK3, TYK2), and interfering with the signaling pathway. They have shown to be successful in cancer and inflammatory diseases to date. Concert Pharmaceuticals currently owns patents for the following three deuterated JAK inhibitors, with indications that each has shown to be effective in, prior to the company adding deuterium to the entity.
D-Ruxolitinib
Selectivity: JAK1,2
Indication: Myelofibrosis, Polycythemia Vera, Alopecia Areata
Patent: 2032 US
D-Baricitinib
Selectivity: JAK1,2, TYK2
Indication: Rheumatoid Arthritis, Psoriasis
Patent: 2032 US
D-Momelotinib
Selectivity: JAK1,2
Indication:
Patent: 2033 US
The non-deuterated versions of these JAK's have already shown proof-of-concept (POC), essentially reducing the risk for Concert to bring the drugs to market, for other or same, previously tested indications. It's rare to have a full runway of patent years ahead, with clinically tested drugs, at your disposal. We'll follow the Janus Kinase landscape with any new findings in the future. Thank you for reading.
D-Ruxolitinib
Selectivity: JAK1,2
Indication: Myelofibrosis, Polycythemia Vera, Alopecia Areata
Patent: 2032 US
D-Baricitinib
Selectivity: JAK1,2, TYK2
Indication: Rheumatoid Arthritis, Psoriasis
Patent: 2032 US
D-Momelotinib
Selectivity: JAK1,2
Indication:
Patent: 2033 US
The non-deuterated versions of these JAK's have already shown proof-of-concept (POC), essentially reducing the risk for Concert to bring the drugs to market, for other or same, previously tested indications. It's rare to have a full runway of patent years ahead, with clinically tested drugs, at your disposal. We'll follow the Janus Kinase landscape with any new findings in the future. Thank you for reading.
No comments:
Post a Comment